The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32––35 weeks: a Canadian-based analysis**

Author： Lanctôôt Krista L.   Masoud Shababa T.   Paes Bosco A.   Tarride Jean-Eric   Chiu Aaron   Hui Charles   Francis Philip L.   Oh Paul I.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.24, Iss.11, 2008-11, pp. : 3223-3237

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

By Joan L. Robinson   Krista L. Lanctôt  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1631-1633

Informa Healthcare

Access to resources Recommend Favorite

Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada*

By Paes Bosco   Steele Susan   Janes Marianne   Pinelli Janet  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1585-1591

Informa Healthcare

Access to resources Recommend Favorite

Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort study

By  

Epidemiology and Infection, Vol. 145, Iss. 2, 2017-01 ,pp. : 266-271

Cambridge University Press

Access to resources Recommend Favorite

Antenatal corticosteroid treatment in singleton, small‐for‐gestational‐age infants born at 24–31 weeks’ gestation: a population‐based study

By  

BJOG : AN INTERNATIONAL JOURNAL OF OBSTETRICS & GYNAECOLOGY, Vol. 123, Iss. 11, 2016-10 ,pp. : 1779-1786

John Wiley & Sons Inc

Access to resources Recommend Favorite

Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands

By  

ACTA PAEDIATRICA, Vol. 104, Iss. 9, 2015-09 ,pp. : 927-932

John Wiley & Sons Inc

Access to resources Recommend Favorite